TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) Director Mats Wahlstrom bought 50,000 shares of the business’s stock in a transaction on Thursday, November 12th. The shares were acquired at an average cost of $2.24 per share, for a total transaction of $112,000.00. Following the transaction, the director directly owned 197,555 shares in the company, valued at approximately $442,523.20. This trade represents a 33.89% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
TriSalus Life Sciences Price Performance
Shares of NASDAQ TLSI opened at $2.43 on Monday. The stock has a market capitalization of $149.63 million, a PE ratio of -4.96 and a beta of 0.50. The stock’s fifty day simple moving average is $4.05 and its two-hundred day simple moving average is $4.29. TriSalus Life Sciences, Inc. has a 12-month low of $2.20 and a 12-month high of $7.95. The company has a current ratio of 4.22, a quick ratio of 3.86 and a debt-to-equity ratio of 47.60.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $14.02 million. As a group, analysts expect that TriSalus Life Sciences, Inc. will post -0.62 EPS for the current fiscal year.
Analyst Ratings Changes
Several analysts have recently commented on the stock. Stifel Nicolaus set a $12.00 price objective on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. HC Wainwright cut their price target on TriSalus Life Sciences from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 11th. Wall Street Zen lowered TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Guggenheim set a $12.00 target price on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Finally, Zacks Research raised TriSalus Life Sciences to a “hold” rating in a report on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.20.
Check Out Our Latest Research Report on TriSalus Life Sciences
Institutional Trading of TriSalus Life Sciences
A number of institutional investors and hedge funds have recently modified their holdings of TLSI. Cura Wealth Advisors LLC acquired a new position in shares of TriSalus Life Sciences during the second quarter valued at approximately $36,000. Russell Investments Group Ltd. purchased a new position in shares of TriSalus Life Sciences in the third quarter worth about $68,000. Provenance Wealth Advisors LLC acquired a new position in TriSalus Life Sciences during the third quarter worth about $94,000. Renaissance Technologies LLC acquired a new position in TriSalus Life Sciences during the first quarter worth about $124,000. Finally, Deutsche Bank AG purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at about $221,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.
About TriSalus Life Sciences
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Read More
- Five stocks we like better than TriSalus Life Sciences
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
